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INTRODUCTION
Secondary hyperparathyroidism is common in patients 
with chronic kidney disease (CKD). Homeostatic mech-
anisms for deranged mineral metabolism start to fail 
at a glomerular filtration rate of 60 mL/min [1]. In fact, 
abnormalities in bone mineral metabolism are nearly 
uniform in stage 4 CKD patients [1]. The worldwide 
population is aging and we are accepting older patients 
with significant comorbidities for dialysis. The criteria 
for selecting patients for long-term renal replacement 
therapy have also been expanded. As a result, there is 
an increasing number of patients requiring treatment 
for hyperparathyroidism since mineral bone disease is 
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inevitable in stage 5 CKD patients. In addition, the impor-
tance and implications of calcium and phosphate dys-
regulation and hyperparathyroidism are not limited to the 
skeleton. Extraskeletal manifestations with fatal out-
comes such as cardiovascular events are linked to bone 
mineral abnormalities [2–4]. In 2005, the organization 
Kidney Disease: Improving Global Outcomes (KIDGO) 
redefined renal osteodystrophy as CKD–mineral and bone 
disorder (CKD-MBD), and the importance of bone 
mineral dysregulation was emphasized [5]. As a result, 
measures to control mineral metabolism and hyperpara-
thyroidism are needed to reduce the cardiovascular burden 
of the already-at-risk CKD population. Although there are 
newer forms of medical treatment such as selective vi-
tamin D analogs and calcimimetics, parathyroidectomy 
(PTx) remains the time-honored treatment modality when 
medical treatment fails [1,6]. What constitutes the optimal 
form of PTx, total or subtotal, with or without autoimplan-
tation, remains undetermined for secondary hyperpara-
thyroidism. In this retrospective review study, we report 
our 25 years of experience in the management of renal 
bone disease.
METHODS
The Renal Unit of Princess Margaret Hospital is a ter-
tiary referral center in Hong Kong. We conducted a 
retrospective review of all stage 5 CKD patients with bone 
biopsies done between 1982 and 2007. Data on baseline 
characteristics, biochemistry, bone histology, operative 
records and imaging findings were retrieved. Bone bi-
opsy was usually indicated for uncontrolled calcium and 
phosphate levels and severe symptoms such as bone pain. 
We biopsied the iliac crest bone with double tetracycline 
labeling. Medical therapy was the first-line treatment 
for secondary hyperparathyroidism with control of 
serum calcium and phosphate levels. Only calcium- and 
aluminium-containing phosphate binders were available. 
Failed medical treatment and progressive extraskeletal 
calcification were the two main indications for PTx. 
Preoperative imaging was either by computed tomog-
raphy (CT) scan of the neck, Tc 99m-sestamibi (MIBI) 
scintigraphy or both. When total PTx was performed, 
excised glands were sent for histological confirmation. 
Autoimplantation of parathyroid tissue was performed 
for patients who were potential candidates for kidney 
transplantation while no autoimplantation was done for 
patients with a low chance for kidney transplantation 
(due either to advanced age or the presence of significant 
comorbidities). The cut-off value for the definition of 
biochemical recurrence of hyperparathyroidism was ar-
bitrarily taken as an intact parathyroid hormone (iPTH) 
level that was 10 times the upper limit of normal.
RESULTS
Between 1982 and 2007, a total of 192 patients on 
chronic dialysis had bone biopsies at the Renal Unit of 
Princess Margaret Hospital. Mean age was 50.95 ± 11.63 
years (Table 1). Peritoneal dialysis was the mode of 
Table 1. Demographic data of patients with bone biopsies from 1982 to 2007*
 All patients Group A (1982–1994) Group B (1995–2007)
Number  192 58 134
Age (yr) 50.95 ± 11.63 47.36 ± 11.73 52.58 ± 1.25
Male:Female 79:113 22:36 57:77
Prevalence of DM  2/25 (8) 17/122 (14)
Duration on dialysis (yr)  6.2 ± 3.89 6.97 ± 5.62
Mode of dialysis   
 HD 69 (36) 32 (56) 37 (28)
 PD 123 (64) 26 (44) 97 (72)
Bone histology    
 Hyperparathyroid bone 167 (86) 40 (69) 126 (94)
 Mixed osteodystrophy 15 (8) 10 (17) 5 (4)
 Adynamic bone 4 (2) 1 (2) 3 (2)
 Osteomalacia 7 (4) 7 (12) 0 (0)
Symptoms (n = 190) (n = 57) (n = 133)
 Bone pain 56 (29) 18 (32) 38 (29)
 Joint pain 24 (13) 8 (15) 16 (12)
 Fracture 10 (5) 5 (8.8) 5 (3.6)
 Muscle weakness 6 (3) 3 (5) 3 (2)
Aluminium hydroxide dosage (g)  3,369 ± 2,612 2,269 ± 2,698
*Data presented as n or mean ± standard deviation or n (%). DM = diabetes mellitus; HD = hemodialysis; PD = peritoneal dialysis.
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Table 2. Correlations between bone histology, aluminium staining 
and total doses of aluminium hydroxide in 12 patients
Histology Aluminium  Aluminium
 stain (%) hydroxide (g)
Hyperparathyroid bone 20 4,464
Hyperparathyroid bone 30 1,168
Hyperparathyroid bone 5–10 432
Hyperparathyroid bone 40 1,296
Hyperparathyroid bone 30 Not available
Hyperparathyroid bone 20–30 3,240
Hyperparathyroid bone < 5 2,790
Hyperparathyroid bone 5–10 1,548
Mixed osteodystrophy 20 3,672
Osteomalacia 50 4,380
Osteomalacia > 50 2,628
Adynamic bone > 70 5,706
dialysis in 64% of patients. Hyperparathyroid bone 
disease predominated (167/192). Patients were divided 
into two groups according to the time of bone biopsy: 
group A from 1982 to 1994 and group B from 1995 to 
2007. There were more patients in group B (134/192) 
than in group A. Patients in group B were older and a 
greater proportion of them were diabetic. The predomi-
nant use of peritoneal dialysis was more obvious in 
group B (72% in group B vs. 44% in group A). In group A, 
hyperparathyroid bone disease, mixed osteodystrophy, 
adynamic bone disease (ABD) and osteomalacia were 
found in 69%, 17%, 2% and 12%, respectively. In group 
B, hyperparathyroid bone disease occurred in 94%, 
mixed osteodystrophy and ABD were present in 4% and 
2%, respectively, and osteomalacia was not observed.
Bone pain was the most frequently reported symp-
tom (Table 1). The total doses of aluminium hydroxide 
used before bone biopsy were 3,369 ± 2,612 g in group A 
and 2,269 ± 2,698 g in group B (Table 1). Thirty-four 
biopsies were positive for aluminium staining: hyperpara-
thyroid bone, 25/34; mixed osteodystrophy, 6/34; osteo-
malacia, 2/34; and adynamic bone, 1/34. Twelve biopsies 
were available for more detailed analysis (Table 2). In 
these 12 cases, various percentages of aluminium stain-
ing were found in different histological types of renal 
osteodystrophy. In particular, osteomalacia and ABD were 
associated with very high levels of aluminium staining.
Seventy-four patients underwent PTx; their mean 
age was 52.46 ± 10.01 years. The characteristics of these 
patients are summarized in Table 3. Neck CT was per-
formed in 55 patients. One single enlarged parathyroid 
gland was seen in 22 (40.0%) patients. Two, three and 
four glands were identified in 15 (27.3%), 2 (3.6%) and 
11 (20.0%) patients, respectively. No enlarged gland 
was seen in five (9.1%) patients. In 23 patients, MIBI 
scintigraphy demonstrated 0, 1, 2, 3 and 4 glands in 2, 
3, 6, 9 and 3 patients respectively.
Four parathyroid glands were identified and removed 
in the majority (43/74) of patients. Fourteen patients 
had three glands removed, two had two glands removed, 
and one had five glands removed. Information on the 
surgical details was incomplete in 14 patients.
Mean preoperative iPTH level was 213 ± 282 pmol/L 
(normal range, 1.3–6.8 pmol/L) (Figure 1). After PTx, 
iPTH levels fell rapidly and remained within 2–5 times 
the upper limit of normal. Serum calcium levels were 
stable at normal levels while serum phosphate levels 
showed remarkable improvement after PTx (Figure 2). 
Calcium × phosphate (Ca × P) product was elevated at 
6.06 mmol2/L2 preoperatively (Figure 3). Postopera-
tively, it was maintained at 3.8–4.58 mmol2/L2 for up to 
5 years of follow-up.
Operative details were available for 68 patients 
(Table 4). Thirty-six of them had autoimplantation to the 
thighs whereas the remaining 32 patients had no auto-
implantation. The baseline characteristics of the two 
groups were similar, except that the no autoimplantation 
group was older. The postoperative iPTH levels and 
serum calcium levels also tended to be lower in the no 
Table 3. Demographic data of the 74 patients who underwent 
parathyroidectomy*
Age (yr) 52.46 ± 10.01
Male:Female 29:45
Primary disease
 Glomerulonephritis 17 (23)
 Polycystic kidney 5 (7)
 SLE 4 (5)
 DM 2 (3)
 Others 6 (8)
 Unknown 40 (54)
HD:PD  31:43
Duration on dialysis (yr) 8.24 ± 6.50
Number of glands on CT (n = 55)
 0 5 (9)
 1 22 (40)
 2 15 (27)
 3 2 (4)
 4 11 (20)
Number of glands on MIBI (n = 23)
 0 2 (9)
 1 3 (13)
 2 6 (26)
 3 9 (39)
 4 3 (13)
Number of glands removed (n = 60)
 2 2 (3)
 3 14 (23)
 4 43 (72)
 5 1 (2)
*Data presented as mean ± standard deviation or n or n (%). 
SLE = systemic lupus erythematosus; DM = diabetes mellitus; 
HD = hemodialysis; PD = peritoneal dialysis; CT = computed 
tomography; MIBI = Tc 99m-sestamibi scintigraphy.
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Figure 3. Calcium × phosphate (Ca × P) product after parathyroid-
ectomy.
autoimplantation group, whereas serum phosphate 
levels were similar in both groups (Figures 4–6).
Eleven (14.86%) of the 74 patients who underwent 
PTx had biochemical recurrences (Figure 7). Six (6/36, 
16.67%) occurred in the autoimplantation group and five 
(5/32, 15.63%) was in the no autoimplantation group. 
Table 4. Demographic data of patients who underwent parathyroid-
ectomy with autoimplantation versus parathyroidectomy without 
autoimplantation*
 Autoimplantation No autoimplantation 
 (n = 36) (n = 32)
Age (yr) 48.78 ± 7.93 57.34 ± 10.35
Male:Female 15:21 11:21
Primary disease  
 Glomerulonephritis  9  8
 Polycystic kidney  2  3
 SLE  1  2
 DM  0  2
 Others  2  1
 Unknown 22 15
HD:PD  16:20 12:20
Duration on 8.61 ± 8.45 7.67 ± 3.82
 dialysis (yr)
*Data presented as mean ± standard deviation or n. SLE = systemic 
lupus erythematosus; DM = diabetes mellitus; HD = hemodialysis; 















Figure 4. Serum intact parathyroid hormone (iPTH) levels after 



















Figure 5. Serum calcium levels after parathyroidectomy with and 
without autoimplantation.
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Figure 6. Serum phosphate levels after parathyroidectomy with and 
without autoimplantation.
of a century, the pattern of bone disease had changed. 
Although hyperparathyroid bone disease remained the 
predominant type of bone disease with an increasing 
prevalence, osteomalacia practically disappeared in the 
latter half of our review period. This was most likely due 
to the reduced exposure to aluminium intake, as evidenced 
by the lower total dose of aluminium hydroxide given to 
patients in the latter half of our study period (Table 1). 
Moreover, an improved water treatment system for hemo-
dialysis may also have contributed to this phenomenon.
In recent years, there has been an increasing incidence 
of ABD worldwide [7]. This is due to various factors, 
such as more elderly patients, more diabetics on dialy-
sis, and relative hypoparathyroidism due to overzealous 
suppression of PTH by active vitamin D therapy. How-
ever, in our study, the percentage of ABD was low (2%) 
in the early (1982–1994) and later (1995–2007) study 
periods. This is most likely due to the fact that most pa-
tients with non-aluminium-related ABD were relatively 
asymptomatic and bone biopsy was not required.
In the Dialysis Outcomes and Practice Patterns Study 
(DOPPS), only 5% of patients on standard therapy 
achieved National Kidney Foundation Kidney Disease 
Outcomes Quality Initiative (KDOQI) targets for calcium, 
phosphate, Ca × P product and iPTH [8]. An important 
complication of uncontrolled bone mineral metabolism 
is accelerated vascular calcification with excessive car-
diovascular morbidity and mortality [2–4,9,10]. Medical 
therapy using active vitamin D and calcium-containing 
phosphate binders can lead to hypercalcemia and hyper-
phosphatemia. Selective vitamin D analogs, calcimimetics 
and non-calcium phosphate binders are expensive and thus 
are not readily available. Long-term results of using these 
new forms of treatment are awaited. On the other hand, 
PTx has been a standard treatment for secondary hyper-
parathyroidism for decades and its beneficial effects have 
been reported extensively. PTx reduces pulmonary, car-
diovascular and soft tissue calcification [11–13]. More 
importantly, long-term survival benefit has been re-
ported in registry data [14,15]. Other beneficial effects 
of PTx include reduced fracture risks, amelioration of 
anemia, reduction in left ventricular hypertrophy, and 
The mean time to recurrence was 1.5 years and 2.8 years 
in the autoimplantation and no autoimplantation groups, 
respectively. In the autoimplantation group, three patients 
had ectopic parathyroid tissues and one of them also had 
recurrent hyperplasia of the implanted tissue. Two pa-
tients had hyperactivity demonstrated in the implanted 
tissues. The recurrence in the last patient was due to in-
complete surgical removal. In the no autoimplantation 
group, three of the five recurrences were suspected to be 
due to incomplete surgical removal as only three glands 
had been removed in the three patients. Of the remaining 
two patients, one died half a year after PTx before any 
detailed investigation could be done. The other patient 
had iPTH levels just exceeding the criteria for recurrence 
and repeated MIBI scintigraphy showed one active spot in 
the neck region. This may have represented incomplete 
surgical removal or the presence of a fifth gland.
No fracture was reported in any of the patients after 
PTx.
DISCUSSION
In this retrospective study, we have reported our experience 
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Figure 7. Causes of biochemical recurrence after parathyroidectomy.
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improvements in cognition and quality of life [13,16–19]. 
In fact, Foley et al reported a fall followed by a rise in PTx 
rates in he modialysis patients from 1992 to 2002 in the 
USA [14]. This may reflect the renewed recognition of the 
need for PTx in the control of secondary hyperthyroidism.
In this study, calcium, phosphate and iPTH levels 
were satisfactorily controlled for up to 5 years after PTx. 
The KDOQI guidelines for bone mineral metabolism 
are difficult to achieve without PTx [20]. The use of 
active vitamin D and calcium-containing binders would 
aggravate the already deranged mineral metabolism, 
especially in the face of severe hyperparathyroidism. 
Newer therapies (e.g. calcimimetics) may be able to 
suppress iPTH with fewer perturbations in calcium and 
phosphate metabolism [21,22]. However, long-term 
results are lacking. The optimal iPTH level for end-stage 
renal failure (ESRF) patients has not been determined. 
Most authorities would suggest a higher-than-normal 
level for optimal bone health in stage 5 CKD patients 
[20,23]. KDOQI proposes to target iPTH levels of 
16.5–33.0 pmol/L for stage 5 CKD [20]. The Caring for 
Australasians with Renal Impairment (CARI) guidelines 
suggest targeting iPTH levels of 1–3 times the upper 
limit of normal [23]. Our patients had postoperative 
mean iPTH levels maintained at 2–5 times the upper 
limit of normal for up to 5 years of follow-up. This is 
in agreement with the KDOQI guidelines. Similar favor-
able changes were observed for serum calcium and 
phosphate levels (Figure 2).
A high rate of recurrence of hyperparathyroidism is 
the major drawback of subtotal PTx or PTx with auto-
implantation [24]. The main cause of recurrence is the 
presence of residual or aberrant parathyroid tissue that 
is constantly stimulated by the uremic milieu. Another 
probable reason for high rates of recurrence is the implan-
tation of parathyroid tissue with nodular hyperplasia. 
Cells in nodular hyperplasia have a significantly lower 
density of vitamin D receptors and calcium-sensing 
receptors compared to cells in normal parathyroid tissue 
[25,26]. Tominaga et al showed that nodular hyperplasia 
was very common in hemodialysis patients with advanced 
hyperparathyroidism who underwent PTx [27]. PTx 
without autoimplantation does not have the issue of au-
tograft recurrence. In our cohort of patients who under-
went PTx with no autoimplantation, three of the five 
recurrences were probably related to incomplete surgical 
removal as only three glands had been removed. In fact, 
these were subtotal PTx. With meticulous surgical tech-
nique and intraoperative iPTH monitoring, true total PTx 
without autoimplantation may result in less recurrence 
[28]. Another point of note was the longer time to recur-
rence in the no autoimplantation group. For ESRF patients 
who are deemed to have a low chance for renal trans-
plantation, longer time to recurrence means less time with 
hyperparathyroidism. This is very significant for patients 
with limited life expectancy. There is concern of low levels 
of iPTH in the no autoimplantation group. However, 
iPTH activity was still detected in total PTx without 
autoimplantation. There may be a fifth gland or residual 
activity due to the presence of isolated parathyroid cell 
nests anywhere along the embryonic descent from the 
third and fourth brachial pouches.
In our study, iPTH levels tended to be lower in the no 
autoimplantation group. In fact, low turnover bone disease 
is the major concern of PTx without autoimplantation. 
Low serum iPTH levels may be associated with higher 
fracture risk and early mortality [29,30]. In one cross-
sectional study of 187 male hemodialysis patients, Atsumi 
et al found that patients with serum iPTH levels in the 
lowest tertile had a greater risk for vertebral fracture 
[29]. Coco and Rush performed a retrospective study 
of 1,271 patients [30]. They reported that patients with 
lower serum PTH levels were more likely to sustain a 
hip fracture and to die earlier. de Francisco et al, on the 
other hand, did not find an excess of fracture in patients 
with post-PTx low bone turnover disease [31]. The dif-
ference may be explained by the fact that adverse out-
comes of ABD before the 1990s were mostly associated 
with aluminium toxicity, whereas ABD in recent years 
has been non-aluminium-related and might be more 
benign [32]. There is still no consensus on whether or 
not non-aluminium-related ABD is harmful. In this 
study, no fracture was reported after PTx.
Renal bone disease is prevalent despite successful 
kidney transplantation and apparent normalization of 
biochemical parameters [33–35]. In particular, ABD has 
been reported to be a common form of bone disease after 
kidney transplantation. The implications of this are still 
being debated. However, it may be advisable to abstain 
from PTx without autoimplantation in patients who are 
on the waiting list for transplantation so as not to induce 
an excessively low parathyroid state post-transplant.
CONCLUSION
The epidemiology of bone disease in stage 5 CKD 
patients has changed in the last quarter of a century. Hy-
perparathyroid bone disease continues to be the pre-
dominant form of renal bone disease. On the other hand, 
aluminium-related osteomalacia has disappeared while 
non-aluminium-related ABD is the only low-turnover 
bone disease we see nowadays.
Medical treatment for secondary hyperparathyroid-
ism cannot always achieve the targets for bone mineral 
metabolism. PTx, on the other hand, has stood the test of 
time. In this study, PTx, with or without autoimplantation, 
produced satisfactory results up to a mean follow-up of 
5 years. Ca × P product was maintained within the rec-
ommended range. iPTH levels were kept at 2–5 times 
of normal, which were conducive to bone health in 
ESRF patients. No fracture was reported after PTx.
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We recommend total PTx without autoimplantation, 
especially in candidates who are not on the waiting list 
for transplantation.
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